These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 15453324)

  • 21. Early hepatitis B virological rebound on entecavir through selection of lamivudine-associated mutations.
    Tong CY; Mullen JE; Wong T
    J Antimicrob Chemother; 2009 Oct; 64(4):875-7. PubMed ID: 19671587
    [No Abstract]   [Full Text] [Related]  

  • 22. Hepatitis B virus-related membranous nephropathy treated with entecavir.
    Ikee R; Ishioka K; Oka M; Maesato K; Moriya H; Hidaka S; Ohtake T; Kobayashi S
    Nephrology (Carlton); 2010 Mar; 15(2):266. PubMed ID: 20470290
    [No Abstract]   [Full Text] [Related]  

  • 23. Monitoring antiviral resistance in patients receiving nucleos(t)ide analog therapies for hepatitis B: which method should be used?
    Degertekin B; Lok AS
    J Hepatol; 2008 Jun; 48(6):892-4. PubMed ID: 18433924
    [No Abstract]   [Full Text] [Related]  

  • 24. Recent advances in antiviral agents.
    Richmond S; Longson M
    Practitioner; 1982 Oct; 226(1372):1711-8. PubMed ID: 6184706
    [No Abstract]   [Full Text] [Related]  

  • 25. [Entecavir - options and obstacles of an effective treatment for chronic hepatitis B].
    Cornberg M; Manns MP
    Dtsch Med Wochenschr; 2010 Jan; 135(1-2):32-7. PubMed ID: 20024882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan.
    Suzuki Y; Kobayashi M; Ikeda K; Suzuki F; Arfase Y; Akuta N; Hosaka T; Saitoh S; Kobayashi M; Someya T; Matsuda M; Sato J; Watabiki S; Miyakawa Y; Kumada H
    J Med Virol; 2005 May; 76(1):33-9. PubMed ID: 15779048
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Common hepatitis B drug linked to HIV antiviral resistance.
    Future Microbiol; 2007 Apr; 2(2):104. PubMed ID: 17687802
    [No Abstract]   [Full Text] [Related]  

  • 28. Potency of tenofovir in chronic hepatitis B: mono or combination therapy?
    Reijnders JG; Janssen HL
    J Hepatol; 2008 Mar; 48(3):383-6. PubMed ID: 18191272
    [No Abstract]   [Full Text] [Related]  

  • 29. Letter: acute hepatitis B - to treat or not to treat?
    Casals-Seoane F; Arberas-Diez B; Moreno-Otero R
    Aliment Pharmacol Ther; 2012 Jul; 36(1):76-7. PubMed ID: 22650494
    [No Abstract]   [Full Text] [Related]  

  • 30. Lamivudine enabled isoniazid and rifampicin treatment in pulmonary tuberculosis and hepatitis B co-infection.
    Yu WC; Lai ST; Chiu MC; Chau TN; Ng TK; Tam CM
    Int J Tuberc Lung Dis; 2006 Jul; 10(7):824-5. PubMed ID: 16850548
    [No Abstract]   [Full Text] [Related]  

  • 31. Drug therapy: antiviral agents (second of two parts).
    Hirsch MS; Swartz MN
    N Engl J Med; 1980 Apr; 302(17):949-53. PubMed ID: 6244492
    [No Abstract]   [Full Text] [Related]  

  • 32. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial.
    Lai CL; Ching CK; Tung AK; Li E; Young J; Hill A; Wong BC; Dent J; Wu PC
    Hepatology; 1997 Jan; 25(1):241-4. PubMed ID: 8985298
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Strategies in the therapy of hepatitis B surface antigen (HBsAg-)-positive chronic hepatitis].
    Hess G; Meyer zum Büschenfelde KH
    Dtsch Med Wochenschr; 1986 Dec; 111(50):1933-7. PubMed ID: 2430769
    [No Abstract]   [Full Text] [Related]  

  • 34. FDA, Bristol-Myers Squibb issue warning on hepatitis B drug.
    AIDS Read; 2007 Oct; 17(10):478-510. PubMed ID: 17987701
    [No Abstract]   [Full Text] [Related]  

  • 35. Effective treatment for de novo hepatitis B with nucleotide analogue in patients with hematological malignancies.
    Ueda Y; Marusawa H; Ichinohe T; Kadowaki N; Uchiyama T; Chiba T
    Am J Hematol; 2009 May; 84(5):315-6. PubMed ID: 19350661
    [No Abstract]   [Full Text] [Related]  

  • 36. Transmission of antiviral drug resistant hepatitis B virus: implications for public health and patient management.
    Locarnini S
    J Gastroenterol Hepatol; 2010 Apr; 25(4):649-51. PubMed ID: 20492319
    [No Abstract]   [Full Text] [Related]  

  • 37. [Treatment of hepatitis B].
    Telegdy L
    Orv Hetil; 2004 Nov; 145(45):2293-6. PubMed ID: 15573894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Think twice if you consider entecavir treatment in cases with lamivudine refractoriness.
    Ustundag Y; Topalak O
    Hepatology; 2010 Jul; 52(1):397-8. PubMed ID: 20229575
    [No Abstract]   [Full Text] [Related]  

  • 39. [Treatment and selection criteria for chronic hepatitis B].
    Gunji T; Omata M
    Nihon Rinsho; 2004 Aug; 62 Suppl 8():309-12. PubMed ID: 15453336
    [No Abstract]   [Full Text] [Related]  

  • 40. Is entecavir ideal for the treatment of lamivudine-refractory chronic hepatitis B?
    Su CW; Wu JC; Lee SD
    Hepatology; 2008 Nov; 48(5):1726-7; author reply 1727-8. PubMed ID: 18972445
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.